Stavudine (d4T), sold under the brand name Zerit among others, is an antiretroviral medication used to prevent and treat HIV/AIDS. It is generally recommended for use with other antiretrovirals. It may be used for prevention after a needlestick injury or other occupational exposure to HIV. Technically, stavudine is a thymidine analogue nucleoside reverse transcriptase inhibitor that is intracellularly phosphorylated to the active triphosphate form, which competes with natural deoxythymidine triphosphate and causes DNA chain termination during reverse transcription. The molecule is chemically defined as 2',3'-didehydro-3'-deoxythymidine and is synthesized via routes that protect the pyrimidine base while modifying the sugar moiety. Clinically relevant properties include oral bioavailability, intracellular accumulation of the active metabolite, elimination predominantly by renal excretion of parent drug, and a safety profile characterized by mitochondrial toxicities such as peripheral neuropathy, lactic acidosis and fat redistribution that inform modern regimen selection and monitoring.
Parent: Stavudine
Parent: Zidovudine / Stavudine
Typical API quality specifications for stavudine used in manufacturing and regulatory submissions include assay by validated HPLC in the range of about 98.0 to 102.0 percent, related substances limits where any single identified related compound is commonly controlled at 0.2 to 0.5 percent maximum and total impurities are typically limited to 1.5 to 2.0 percent, with an unspecified/unknown impurity reporting threshold set at 0.05 to 0.1 percent depending on the control strategy. Common related compounds and degradation products observed during synthesis and stability testing include positional isomers and epimers of the nucleoside, deamination products, hydrolytic cleavage products of the glycosidic bond, and minor oxidative or condensation byproducts. Typical auxiliary limits for finished API batches include residual solvents controlled to ICH Q3C limits, heavy metals not exceeding 20 parts per million unless otherwise justified, and water content generally targeted at or below 0.5 percent by Karl Fischer.
Zidovudine and stavudine are both thymidine analogue NRTIs that can exhibit antagonism when used together and share overlapping mitochondrial toxicities; combining them increases risk of adverse effects without clinical benefit, so guidelines advise against coadministration.
Stavudine is used as part of combination antiretroviral therapy to treat HIV infection and has been used for post-exposure prophylaxis following occupational exposures; it reduces viral replication by inhibiting reverse transcriptase after intracellular phosphorylation to its active triphosphate.
Other names for stavudine include d4T and the brand name Zerit; its chemical name is 2′,3′-didehydro-3′-deoxythymidine.
Stavudine remains available in some markets as generic and branded formulations, but its use has been substantially reduced or phased out in many national programs in favor of antiretrovirals with better safety profiles; current availability depends on local regulatory approvals and procurement decisions.
